Northwest Biotherapeutics (NWBO)
(Delayed Data from OTC)
$0.33 USD
+0.01 (4.52%)
Updated Sep 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Northwest Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 7 | 15 | 10 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 6 | 3 |
Total Current Assets | 4 | 9 | 17 | 16 | 3 |
Net Property & Equipment | 17 | 13 | 15 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 0 |
Deposits & Other Assets | 0 | 2 | 1 | 10 | 1 |
Total Assets | 28 | 31 | 40 | 33 | 9 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 30 | 24 | 7 | 6 | 6 |
Accounts Payable | 14 | 18 | 11 | 13 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 84 | 115 | 363 | 27 |
Total Current Liabilities | 45 | 126 | 134 | 382 | 41 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 5 | 0 | 0 |
Other Non-Current Liabilities | 25 | 6 | 25 | 9 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 75 | 136 | 164 | 396 | 53 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 19 | 23 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,291 | 1,165 | 1,067 | 1,009 | 795 |
Retained Earnings | -1,360 | -1,297 | -1,192 | -1,371 | -840 |
Other Equity | 1 | 3 | 0 | -1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -47 | -105 | -124 | -363 | -44 |
Total Liabilities & Shareholder's Equity | 28 | 31 | 40 | 33 | 9 |
Total Common Equity | -66 | -128 | -124 | -363 | -44 |
Shares Outstanding | 1,185.60 | 1,069.00 | 954.50 | 824.20 | 625.40 |
Book Value Per Share | -0.06 | -0.12 | -0.13 | -0.44 | -0.07 |
Fiscal Year End for Northwest Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 2 | 2 | 6 | 1 |
Receivables | 0 | 0 | 0 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 2 | 2 | 3 |
Total Current Assets | 5 | 5 | 4 | 8 | 5 |
Net Property & Equipment | 17 | 17 | 17 | 17 | 17 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 2 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 28 | 29 | 28 | 31 | 28 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 31 | 34 | 30 | 31 | 10 |
Accounts Payable | 18 | 18 | 14 | 17 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 10 | 1 | 1 | 2 |
Total Current Liabilities | 56 | 62 | 45 | 49 | 40 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 25 | 25 | 16 | 20 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 86 | 82 | 75 | 69 | 64 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 19 | 20 | 19 | 28 | 25 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,316 | 1,301 | 1,291 | 1,271 | 1,258 |
Retained Earnings | -1,396 | -1,378 | -1,360 | -1,341 | -1,322 |
Other Equity | 2 | 2 | 1 | 3 | 2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -58 | -53 | -47 | -37 | -36 |
Total Liabilities & Shareholder's Equity | 28 | 29 | 28 | 31 | 28 |
Total Common Equity | -76 | -73 | -66 | -65 | -61 |
Shares Outstanding | 1,246.20 | 1,205.60 | 1,185.60 | 1,149.30 | 1,117.90 |
Book Value Per Share | -0.06 | -0.06 | -0.06 | -0.06 | -0.05 |